BackTable Tumor Board

When first-line treatment for advanced hepatocellular carcinoma (HCC) fails and the disease progresses, what options are available for second-line therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi explore the uncertain landscape of second-line treatment after first-line immunotherapy, such as atezolizumab and bevacizumab or the STRIDE regimen, including practical considerations for choosing which second-line therapy to use. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction01:15 - Second-Line Treatment for HCC: Lenvatinib vs Ramucirumab04:28 - Tolerability And Sequencing Reality: Cabozentinib06:35 - Treatment Options for Rapid Progression After Atezolizumab + Bevacizumab11:40 - Practical Tyrosine Kinase Inhibitor Dosing for HCC13:44 - Next-Generation Sequencing vs Biopsy In HCC Practice19:10 - Future Biomarker Clinical Trials: Risks and Impact on Practice24:31 - Role of Second-Line Immunotherapy in HCC --- More about this episode The doctors discuss real-world dosing strategies for tyrosine kinase inhibitors (TKI), management of rapid progression, and the limited utility of next-generation sequencing and biopsy in HCC. They also highlight ongoing biomarker clinical trials and the evolving role of second-line immunotherapy. They note that few patients reach third-line therapy due to declining performance status and liver function, as well as mixed results from adding CTLA-4 inhibitors after disease progression. --- Resources HIMALAYA Clinical Trialhttps://www.annalsofoncology.org/article/S0923-7534(24)00049-8/fulltext --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Learn how a “watershed” clinical trial in 2020 completely overturned a decade of standard care for liver cancer. In this inaugural episode of the BackTable 2026 HCC Creator Weekend™ , medical oncologists Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the evolution of first-line systemic therapy for hepatocellular carcinoma (HCC), highlighting immune checkpoint inhibitors as a major change from the TKI era. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction03:24 - Early Immunotherapy Momentum07:03 - Long Term Survival Tails14:13 - Autoimmune Disease Nuances22:45 - Combining With Liver Directed Therapy25:29 - Ideal Candidate for Ipi Nivo26:54 - Wrap Up and Takeaways --- More about this episode The doctors discuss key data from IMbrave150 (atezolizumab/bevacizumab vs sorafenib), HIMALAYA (STRIDE: tremelimumab plus durvalumab vs sorafenib), and CheckMate 9DW (ipilimumab/nivolumab vs physician’s choice TKI, largely lenvatinib), noting improved survival, high response rates with ipi/nivo, and long-term survival “tails.” They cover negative/neutral TKI-IO trials (LEAP-002, COSMIC-312) and focus on patient selection nuances including EGD/variceal bleeding risk with bevacizumab, hypertension/proteinuria, platelet thresholds, autoimmune disease considerations, Child-Pugh status, liver function preservation, and preferences when combining systemic therapy with liver-directed procedures like Y90. --- Resources IMbrave150https://www.nejm.org/doi/full/10.1056/NEJMoa1915745 Himalaya Studyhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 CHeckmate 040https://jamanetwork.com/journals/jamaoncology/fullarticle/2771012 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Here’s a practical guide on how biomarkers can guide treatment and cut costs for your breast cancer patients. In this episode of the BackTable Tumor Board Podcast, Dr. Lindsay Peterson and Dr. Jessica Trevino Jones review the role of precision medicine and biomarkers in early-stage and metastatic disease, specifically in breast cancer. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction05:30 - Genomic Testing in the Metastatic Setting11:47 - Liquid vs Tissue Biopsy17:51 - Testing and Treatment for Triple Negative Metastatic Breast Cancer21:20 - Precision Medicine and Patient Education27:01 - Path CR and Residual Disease: Clinical Trials37:01 - Neratinib in Triple Positive Breast Cancer and Brain Metastasis39:55 - Genomic Tests: Oncotype and MammaPrint43:45 - Importance of Clinical Trials and Wellness Support --- More about this episode Dr. Peterson and Dr. Trevino Jones discuss the optimal timing for tumor genomic testing in ER-positive/HER2-negative and triple-negative metastatic breast cancer, and examine the decision-making process between liquid biopsy and tissue biopsy for biomarker analysis. The conversation also highlights how these technological advances can expand treatment options and help reduce financial toxicity for patients. Additionally, the doctors emphasize the importance of patient education about clinical trials, address common misconceptions, and discuss the integration of prevention, nutrition, exercise, and wellness support into comprehensive cancer care. --- Resources OFSET Clinical Trialhttps://clinicaltrials.gov/study/NCT05879926 SWOG 2206 Clinical Trialhttps://www.swog.org/clinical-trials/s2206 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Path CRhttps://clinicaltrials.gov/study/NCT05812807 KETNOTE-522 Clinical Trialhttps://clinicaltrials.gov/study/NCT03036488https://www.nejm.org/doi/full/10.1056/NEJMoa1910549 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

How will the newest colorectal cancer trial results discussed at the 2026 ASCO GI Cancers Symposium in San Francisco impact patient care and therapeutic strategies? Medical oncologists Dr. Shruti Patel and Dr. Jun Gong dissect evidence from multiple practice-changing studies, translating complex data into practical recommendations. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction01:50 - BREAKWATER Trial for Metastatic CRC11:31 - COMMIT Trial for Metastatic CRC dMMR17:34 - STELLAR-303 Trial for Refractory CRC26:03 - ALASCCA Trial on Adjuvant Low Dose Aspirin in CRC31:29 - CHALLENGE Trial on Structured Exercise Programs38:48 - ATOMIC Trial on Adjuvant Immunotherapy44:34 - The Role of GLP-1s in CRC Prevention --- More about this episode Dr. Patel and Dr. Gong cover key findings and takeaways from recent colorectal cancer studies, including BREAKWATER, COMMIT, STELLAR-303, ALASCCA, CHALLENGE, and ATOMIC. BREAKWATER evaluates first-line targeted therapy combinations in BRAF V600E–mutant metastatic CRC, demonstrating improved response rates and progression-free survival with the addition of encorafenib-based regimens. COMMIT investigates the role of immunotherapy with or without chemotherapy in dMMR metastatic CRC, helping clarify whether upfront chemotherapy adds benefit to checkpoint blockade in this population.STELLAR-303 examines a novel therapeutic option in refractory CRC, comparing a new agent against standard therapies and showing modest survival benefit in heavily pretreated patients. ALASCCA assesses the impact of adjuvant low-dose aspirin in biomarker-selected CRC patients, suggesting improved disease-free survival in patients with PI3K pathway alterations. CHALLENGE evaluates structured exercise interventions in the post-treatment setting, demonstrating that increased physical activity is associated with improved disease-free survival and overall outcomes.ATOMIC explores the addition of immunotherapy to standard adjuvant chemotherapy in resected dMMR CRC, supporting a potential shift toward incorporating checkpoint inhibitors in earlier-stage disease. --- Resources BREAKWATER Trial Cohort 3 Studyhttps://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.13 COMMIT Phase 3 Trialhttps://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.14 STELLAR-303 Phase 3 Trialhttps://pubmed.ncbi.nlm.nih.gov/41130252/ Immunotherapy Efficacy in Mismatch Repair-Proficient Colorectal Cancer Patients With and Without Liver Metastaseshttps://ascopubs.org/doi/10.1200/JCO-25-01044 ALASCCA Trialhttps://clinicaltrials.gov/study/NCT02647099?tab=studyCHALLENGE Phase 3 Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA3510Regular Physical Activity Can Help Manage CRC-Related Fatiguehttps://dailynews.ascopubs.org/do/regular-physical-activity-can-help-manage-crc-related-fatigue ATOMIC Phase 3 Trialhttps://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1 GLP-1 Receptor Agonist vs Aspiring for Primary Prevention of Colorectal Cancerhttps://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.18 ---BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Don’t miss the “curative window”! This episode takes a closer look at how evolving perioperative strategies and biomarker integration are changing bladder cancer care, with a focus on preserving opportunities for cure. Jun Gong hosts Tyler Stewart to review key bladder cancer updates from ASCO Genitourinary Cancers Symposium 2026. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction01:50 - KEYNOTE-905 Overview07:09 - Practice-Changing Takeaways13:28 - Bladder Preservation Trials16:06 - ctDNA Biomarker Updates21:16 - Using ctDNA in Clinic28:48 - Metastatic ADC Data33:36 - Wrap-Up --- More about this episode The discussion begins with KEYNOTE-905/EV-303 in cisplatin-ineligible muscle-invasive bladder cancer, where perioperative enfortumab vedotin plus pembrolizumab demonstrated improvements in event-free and overall survival. This is followed by KEYNOTE-B15, which compares perioperative EVP with gemcitabine/cisplatin and identifies EVP as the first non-platinum regimen to outperform cisplatin-based therapy. Implications for clinical adoption are considered, including the potential for EVP to extend across cisplatin eligibility groups, unresolved questions regarding perioperative duration and adjuvant use, and the need to avoid premature de-escalation outside of trial settings.The latter portion of the episode focuses on biomarker-driven decision-making. Data from RETAIN-2 highlight the prognostic value of post-neoadjuvant ctDNA positivity for systemic relapse risk, while underscoring its limitations in detecting intravesical recurrence. Complementary findings from NIAGARA suggest that urine tumor DNA may more accurately reflect local disease burden and pathologic complete response. Together, these studies frame an evolving role for circulating and urine-based biomarkers in guiding surveillance, treatment selection, and timing—central considerations in maintaining the curative window. --- Resources KEYNOTE-B15https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.LBA630 KEYNOTE-905https://www.nejm.org/doi/abs/10.1056/NEJMoa2511674 EV-302 Clinical Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2312117

When to test, how to prevent, and what you need to know about hereditary gynecologic cancer syndromes. Two USC gynecologic oncologists, Dr. Mona Guo and Dr. Marcia Ciccone, go in-depth in this BackTable OBGYN x Tumor Board crossover episode. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction01:37 - Why Hereditary Cancer Matters04:51 - Family History Red Flags09:01 - Who Should Order Genetic Testing11:32 - Variants and Counseling Pitfalls13:30 - Access and Remote Testing Options19:27 - BRCA1 Positive Patient Walkthrough24:52 - Risk-Reducing Surgeries29:11 - Prevention and Screening Limits32:38 - Why Ovarian Cancer Is Hard34:04 - Combining Breast and Gyn Surgery35:41 - Preop Ultrasound and CA-12536:27 - BRCA Timing and HRT Nuance42:32 - Nonhormonal Menopause Options47:14 - Lynch Syndrome Screening Basics54:22 - Endometrial Biopsy Debate56:43 - Insurance and Coverage Pitfalls59:00 - Fertility Preservation and REI01:01:41 - Cascade Testing01:02:45 - Conclusion --- More about this episode Dr. Guo and Dr. Ciccone discuss how careful family history can identify patients who may benefit from genetic evaluation and highlight key red flags, including a family history of ovarian cancer, breast cancer at age 50 or younger, and metastatic prostate cancer. They explain the role of genetic counseling, including pre- and post-test discussions and how to approach variants of uncertain significance. They then cover BRCA counseling and risk-reduction strategies, including the timing of risk-reducing bilateral salpingo-oophorectomy, ongoing salpingectomy trials, and considerations for hysterectomy. Additionally, they touch on pathology protocols, breast cancer screening, and the potential protective effect of hormonal contraception. The doctors address the limitations of ovarian cancer screening and outline patterns suggestive of Lynch syndrome, such as endometrial cancer occurring alongside gastrointestinal or urinary tract cancers. They review the Lynch workup, including tumor mismatch repair immunohistochemistry and MLH1 hypermethylation testing. Finally, they discuss practical considerations like barriers to access, Medicare coverage challenges, fertility preservation referrals, menopause management, and cascade testing in families, including the timing of testing in children. --- Resources NCCN Guidelines: Detection, Prevention, and Risk Reductionhttps://www.nccn.org/guidelines/category_2

Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction01:46 - How ADCs Work08:40 - ILD Risk and Monitoring13:46 - Next-Generation HER2 ADCs24:14 - HER2-Low and Ultralow Disease29:56 - Sequencing After Endocrine Therapy33:42 - Future Targets and Bispecifics38:08 - Wrap Up --- More about this episode The discussion outlines ADC mechanisms and recent trial-driven shifts in clinical practice, with emphasis on interstitial lung disease (ILD) risk, monitoring, and patient counseling. They address practical considerations including patient selection, sequencing after endocrine therapy, and potential maintenance approaches. Additional topics include evolving pathology reporting, considerations for earlier-stage use in high-risk patients, and the development of next-generation HER2- and HER3-targeted ADCs, as well as bispecific therapies. --- Resources DESTINY Breast 09https://www.nejm.org/doi/full/10.1056/NEJMoa2508668 DESTINY Breast 05https://www.nejm.org/doi/full/10.1056/NEJMoa2514661 DESTINY Breast 06https://www.nejm.org/doi/abs/10.1056/NEJMoa2407086

When standard-of-care checkpoint blockade fails in metastatic melanoma, how can oncologists and interventional radiologists join forces to turn around patient outcomes? In this episode of the BackTable Podcast, medical oncologist Dr. Jennifer McQuade and interventional radiologist Dr. Rahul Sheth join host Dr. Tyler Sandow to discuss the growing evidence for intratumoral oncolytics as a therapeutic strategy for frontline immunotherapy-refractory melanoma and the interdisciplinary work that is required for successful implementation in practice. --- This podcast is supported by:Replimunehttps://www.replimune.com/ --- SYNPOSIS The physicians review how engineered viral vectors, particularly RP1, complement checkpoint blockade through direct tumor lysis and immune activation, and summarize the IGNYTE trial data supporting their use in patients with metastatic melanoma refractory to anti-PD-1 and anti-CTLA-4 agents. The discussion then shifts to practical administration, highlighting the central role of interventional radiology in delivering these therapies to visceral and deep-seated lesions under image guidance. The doctors go on to address the nuances of patient and lesion selection, injection technique, and response assessment, including the importance of recognizing pseudo-progression. They place particular emphasis on the need for multidisciplinary collaboration and stakeholder buy-in efforts on the part of IRs seeking to integrate intratumoral oncolytic injections into their scope of practice. The episode concludes with a forward-looking discussion on the potential for expansion of oncolytic platforms into other solid tumors, underscoring this field as a growing, IR-forward frontier in cancer treatment. --- TIMESTAMPS 00:00 - Introduction02:28 - Immunotherapy Basics06:51 - How Oncolytic Viruses Work11:01 - IGNYTE Trials and Why IR Matters18:14 - T-VEC vs RP1 Indications and Logistics21:57 - Physician Communication and Multidisciplinary Treatment23:06 - RP1 Protocol and Administration Techniques30:28 - RP1 Safety Profile32:46 - Follow-Up Imaging and Response Assessment35:44 - Future Applications Beyond Melanoma41:42 - Final Thoughts and Closing Remarks --- RESOURCES Wong MK, et al. RP1 Combined With Nivolumab in Advance Anti-PD-1-Failed Melanoma (IGNYTE). J Clin Oncol. 2025;43(33):3589-3599.https://doi.org/10.1200/jco-25-01346 IGNYTE-3 Trialhttps://clinicaltrials.gov/study/NCT06264180

Though relatively new, there is a rapidly growing interest in the field of therapeutic radiopharmaceuticals and their potential to play a significant role in cancer treatment. This episode of BackTable Tumor Board covers recent developments in radiopharmaceutical therapies with radiation oncologists Dr. Dustin Boothe and Dr. Ryan Funk, where they discuss efficacy, side effects, and better tolerability of modern radiopharmaceuticals compared to older ones. --- This podcast is supported by: Siemens Healthineers https://cancercare.siemens-healthineers.com/products/software/digital-oncology/aria-core-for-theranostics --- SYNPOSIS Dr. Boothe and Dr. Funk cover the roles of radiation oncologists in treating patients and collaborating with different specialists, the challenges in starting a radiopharmaceutical program, and the importance of having an authorized user and radioactive materials license. They also delve into the promising future of radiopharmaceuticals, emphasizing potential advancements such as personalized dosimetry, new indications, and combination therapies. --- TIMESTAMPS 00:00 - Introduction02:54 - Understanding Radiopharmaceutical Terminology04:40 - The Evolution of Radiopharmaceuticals07:07 - The Rise of Targeted Radiopharmaceutical Therapies12:35 - Radiation Oncologists’ Role in Systemic Therapy23:55 - Challenges and Strategies in Practice Development30:33 - Starting Up a Radiopharmaceutical Practice: Challenges, Authorized Users & RAM Licensing37:47 - Advancing Practices with Clinical Trials and Dosimetry44:48 - Future of Radiopharmaceutical Therapy52:39 - Final Thoughts --- RESOURCES Siemens Healthineers: ARIA CORE for Theranosticshttps://cancercare.siemens-healthineers.com/products/software/digital-oncology/aria-core-for-theranostics PREEMPT Trial (NRG-CC014)https://clinicaltrials.gov/study/NCT06745024#collaborators-and-investigators Community Theranosticshttps://www.communitytheranostics.com/

Inflammatory breast cancer (IBC) is rare but highly aggressive, and often hides in plain sight. Rather than presenting as the distinct lump, IBC typically appears as redness or swelling in the breast and skin changes that can mimic mastitis or infection, leading to dangerous delays in diagnosis. In this episode of BackTable Tumor Board, breast medical oncologists Dr. Lindsay Peterson and Dr. Bora Lim break down how to recognize IBC’s typical and atypical presentations, approach diagnostic workup, and tailor treatment across subtypes. --- SYNPOSIS Dr. Peterson and Dr. Lim explore evolving neoadjuvant strategies, emerging clinical trials, combination therapies, IBC vaccine development, and the growing role of AI and MRI pattern recognition in predicting recurrence and guiding surveillance. The discussion highlights the importance of multidisciplinary expertise and calls for broader clinician awareness–especially in primary care, dermatology, and urgent care–so that persistent “infection-like” breast changes prompt timely evaluation and treatment for IBC. --- TIMESTAMPS 0:00 - Introduction3:26 - Typical Presentations of Inflammatory Breast Cancer (IBC)8:30 - Atypical Presentations of IBC11:48 - Routine Diagnostic Workup16:06 - Treatments for Different Subtypes of IBC19:49 - Clinical Trials22:53 - Surveillance for Different Stages of IBC25:59 - Current Clinical Trials for Best Treatments29:18 - Central Nervous System Recurrence and Other Relapse Patterns in IBC33:29 - Novel Neoadjuvant Therapy 37:27 - Centers Dedicated to Treating IBC42:13 - Final Thoughts --- RESOURCES Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancerhttps://clinicaltrials.gov/study/NCT03202316?tab=researcher#study-record-dates Dana-Farber Cancer Institutehttps://www.dana-farber.org/cancer-care/treatment/breast-oncology/programs/inflammatory-breast-cancer MD Anderson Inflammatory Breast Cancer Clinichttps://www.mdanderson.org/patients-family/diagnosis-treatment/care-centers-clinics/breast-center/inflammatory-breast-cancer-clinic.html

In a patient with metastatic HER2-positive breast cancer, what should guide the next decision: trial data, toxicity, or durability of response? In this episode of BackTable Tumor Board, Dr. Lindsay Peterson (Washington University) sits down with Dr. Erica Hamilton (Sarah Cannon Research Institute) to examine how next-generation HER2-directed therapies are reshaping the management of metastatic disease. As treatment options expand beyond trastuzumab-based regimens to agents such as trastuzumab deruxtecan and tucatinib, clinical decision-making increasingly hinges on sequencing strategy, interpretation of evolving trial data, and thoughtful toxicity management. --- SYNPOSIS The discussion integrates findings from pivotal studies including DESTINY-Breast09 and PATINA, highlighting how these data influence frontline and maintenance approaches. Dr. Hamilton outlines practical considerations in balancing depth and durability of response with quality-of-life concerns, and how she approaches therapy transitions in real-world practice. The episode also explores the management of CNS involvement within the broader systemic treatment landscape and considers whether current advances meaningfully shift long-term outcomes for patients with HER2-positive metastatic breast cancer. --- TIMESTAMPS 00:00 - Introduction01:16 - Metastatic HER2-Positive Breast Cancer06:46 - Treatment Strategies and Patient Management11:57 - Maintenance Therapy Options16:28 - HER2-Positive Breast Cancer Trials20:13 - Brain Metastases and Systemic Therapy27:38 - Future Directions in HER2-Positive Breast Cancer --- RESOURCES DESTINY-Breast09 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2508668 PATINA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2511218 HER2CLIMB Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1914609

Bispecific antibodies are emerging as an important therapeutic class in non-small cell lung cancer (NSCLC); but how do they work, where do they fit in clinical practice, and what should oncologists be thinking about next? In this episode of Back Table Tumor Board, Dr. Kate Baker and Dr. Wade Iams from Tennessee Oncology answer these questions and more. --- SYNPOSIS Dr. Baker and Dr. Iams discuss the evolving role of bispecific antibodies in NSCLC, covering the clinical data behind amivantamab, the practical benefits of subcutaneous vs IV administration, and key considerations for managing unique bispecific-related toxicities in real-world practice. This episode also explores emerging data in NSCLC, highlighting tarlatamab and its promising results in various treatment scenarios, including potential earlier-stage applications. --- TIMESTAMPS 00:00 - Introduction 01:14 - Recent Developments in Bispecific Antibodies03:24 - Real-World Application of MARIPOSA Trial Data04:28 - Managing Toxicities and Side Effects06:28 - CNS Disease and Efficacy of Combination Therapy08:26 - Counseling Patients on Prognosis and Treatment Options12:45 - Challenges in Rolling Out New Treatments in Rural Areas18:21- Future Directions in Non-Small Cell Lung Cancer20:57 - BiTE Therapies in Small Cell Lung Cancer35:00 - Final Thoughts --- RESOURCES MARIPOSA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2503001 FLAURA2 Trialhttp://pubmed.ncbi.nlm.nih.gov/37937763/ COPERNICUS Trialhttps://clinicaltrials.gov/study/NCT06667076 DeLLphi-304 Trialhttps://clinicaltrials.gov/study/NCT05740566?tab=results

Pulsed electric field (PEF) therapy is an emerging cancer treatment that utilizes short electrical pulses to disrupt tumor cell membranes, leading to cell death—all without the risk of thermal damage seen in traditional ablation. How does this novel approach compare to gold-standard treatments like stereotactic body radiation therapy (SBRT) in primary and metastatic lung cancer? Find out in this episode of the BackTable Podcast featuring NYU radiation oncologist Dr. Benjamin Cooper, radiology professor Dr. William Moore, and cardiothoracic surgery professor Dr. Daniel Sterman. --- SYNPOSIS The doctors break down the unique mechanism of PEF and its potential immunological benefits over other ablation techniques like cryoablation and microwave ablation. They also discuss PEF’s evolving role in both primary and metastatic cancer, its integration with therapies like SBRT, procedural efficiency and safety considerations, and why multidisciplinary collaboration and clinical trials are critical to defining its future in lung cancer care. --- TIMESTAMPS 00:00 - Introduction01:38 - Understanding Pulsed Electric Field (PEF) Ablation05:36 - Comparing Ablation Techniques: Cryoablation vs Microwave Ablation vs PEF Ablation10:08 - Potential Immunological Responses, Safety, and Efficacy of PEF23:40 - The Imprint Lung Trial: Exploring Immune System Stimulation in Cancer Treatment29:18 - Patient Case Studies and Treatment Outcomes32:41 - Challenges in Post-Treatment Imaging36:41 - Procedure Times and Techniques for Ablation41:51 - Comparing Pneumothorax Rates in Different Ablative Technologies43:56 - Future Directions and Collaborative Efforts in Cancer Treatment --- RESOURCES PEF in Stage IV Lung Cancerhttps://pubmed.ncbi.nlm.nih.gov/40409026/ IMPRINT-Lung Trialhttps://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2018-01588 Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumorshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12754119/ FLASH Radiotherapyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC9591027/

Is the era of cisplatin over, or are we simply becoming more precise about who benefits from it? As perioperative strategies in bladder cancer continue to evolve, emerging tools like circulating tumor DNA (ctDNA) are playing a bigger role in how clinicians assess recurrence risk and tailor treatment. In this episode of BackTable Tumor Board, host Alan Tan, medical oncologist at Vanderbilt-Ingram Cancer Center, is joined by bladder cancer experts Dr. Amanda Nizam and Dr. Brad McGregor to discuss recent advances in the diagnosis and treatment of urothelial carcinoma. --- SYNPOSIS The doctors examine the evolving management of muscle-invasive bladder cancer (MIBC), including the role of neoadjuvant and adjuvant therapies, the integration of immunotherapy, and the recent approval of enfortumab vedotin plus pembrolizumab. The discussion explores the rapidly changing perioperative landscape, the prognostic utility of ctDNA, and how biomarkers such as HER2 and FGFR are influencing treatment selection across disease states. They also address bladder preservation strategies, management of treatment-related toxicities, and the importance of multidisciplinary coordination. The episode concludes with a forward-looking discussion on emerging therapies and the potential to improve cure rates in bladder cancer. --- TIMESTAMPS 00:00 - Introduction01:44 - Overview of Bladder Cancer Treatment04:54 - Patient Staging and Treatment Goals10:12 - Bladder Preservation vs. Radical Cystectomy16:39 - Emerging Trials and Future Directions22:40 - ctDNA and Precision Medicine33:50 - Metastatic Disease and Biomarker Strategies42:16 - Managing Neuropathy in Metastatic Treatment48:44 - HER2 and FGFR in Bladder Cancer54:15 - Future Directions in Bladder Cancer Treatment --- RESOURCES EV-302/303 Trialhttps://newsroom.astellas.com/2023-12-15-PADCEV-R-enfortumab-vedotin-ejfv-with-KEYTRUDA-R-pembrolizumab-Approved-by-FDA-as-the-First-and-Only-ADC-Plus-PD-1-to-Treat-Advanced-Bladder-Cancer NIAGARA Regimenhttps://www.nejm.org/doi/full/10.1056/NEJMoa2408154 KEYNOTE-905 Studyhttps://www.annalsofoncology.org/article/S0923-7534(25)04894-X/fulltext

The FLOT regimen is the standard-of-care for upper gastroesophageal malignancies, but what if there were other drug combinations or perioperative strategies that could further improve outcomes? In Part II of our ESMO 2025 recap, medical oncologists Dr. Jun Gong and Dr. Jonathan Mizrahi cover emerging studies and treatments in gastroesophageal cancers. --- SYNPOSIS The discussion provides an overview of pivotal trials, including MATTERHORN, which demonstrated improved overall survival with durvalumab plus FLOT, and FORTITUDE-10, which highlights ongoing challenges in treatment efficacy with FGFR2b inhibitors. This episode also explores the role of lenvatinib-based combinations for esophageal squamous cell carcinoma and practical considerations for integrating checkpoint inhibitors into real-world clinical practice. --- TIMESTAMPS 00:00 - Introduction01:23 - The MATTERHORN Study03:24 - PD-L1 Status and Clinical Implications07:09 - FORTITUDE-101 and 102 Studies: Discrepancies and Insights on FGFR2b Inhibition11:15 - LEAP-014 and 015 Studies: The Role of Lenvatinib14:57 - Conclusion and Final Thoughts --- RESOURCES Phase III MATTERHORN Studyhttps://dailynews.ascopubs.org/do/matterhorn-durvalumab-chemotherapy-demonstrates-superior-efs-over-standard-care ESOPEC Phase III Trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4952147/ FORTITUDE-101 Trialhttps://clinicaltrials.gov/study/NCT05052801 FORTITUDE-102 Trialhttps://clinicaltrials.gov/study/NCT05111626 LEAP-014 Phase III Studyhttps://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.TPS367 LEAP-015 Studyhttps://ascopubs.org/doi/10.1200/JCO-25-00748

Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board recap! Featuring medical oncologists Dr. Jonothan Mizrahi and Dr. Jun Gong. --- SYNPOSIS The doctors discuss the DESTINY-CRC02 trial with focus on HER-2 positive metastatic colorectal cancer, the DYNAMIC-III and Pegasus studies regarding CTDNA-guided therapies, and the pivotal STELLAR-303 study for treatment-refractory microsatellite stable colorectal cancer. They also review the implications of NICHE-2 and FOxTROT studies on neoadjuvant chemotherapy versus immunotherapy for MSI high patients. Emphasis is placed on the real-world practice applications of these study findings, potential treatment shifts, and how these new trial results will impact future guidelines in colorectal cancer care. --- TIMESTAMPS 00:00 - Introduction01:25 - Overview of ESMO 2025 Annual Congress13:50 - cTDNA Monitoring in Clinical Practice16:24 - STELLAR-303 Study: Immunotherapy in MSS Colorectal Cancer20:40 - Neoadjuvant Immunotherapy for MSI High Colorectal Cancer26:39 - DESTINY-CRC02 Study: Final Analysis29:30 - Conclusion and Outro --- RESOURCES DESTINY-CRC02 Trialhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/abstract DYNAMIC-III Trialhttps://www.nature.com/articles/s41591-025-04030-w STELLAR-303 Trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02025-2/abstract

For the small subset of pancreatic cancer patients whose cancer is detected early and remains localized, there are now opportunities to offer treatment and improve outcomes. In this episode of the BackTable Tumor Board Podcast, Ochsner medical oncologist Dr. Jonathan Mizrahi and MD Anderson surgical oncologist Dr. Rebecca Snyder discuss the contemporary management of localized pancreatic cancer. --- SYNPOSIS Dr. Snyder and Dr. Mizrahi break down the categories of resectable, borderline resectable, and locally advanced pancreatic cancer; and explain the current treatment strategies that are tailored to each stage. The discussion highlights the role of neoadjuvant therapy, the potential benefits of radiation for certain subpopulations, and the importance of a multidisciplinary team approach for optimal patient care. The doctors also cover pivotal clinical trials, ongoing research, and future directions in the field, including targeted therapies and biomarker development, to inform best practices in treating patients with localized pancreatic cancer. --- TIMESTAMPS 00:00 - Introduction02:24 - Defining Resectable, Borderline, and Locally Advanced Pancreatic Cancer11:10 - Neoadjuvant Therapy for Resectable Pancreatic Cancer17:16 - Ongoing Clinical Trials: FOLFIRINOX and Gemcitabine Nab-Paclitaxel23:04 - The Role of Radiation in Pancreatic Cancer Treatment26:52 - Treating Locally Advanced Pancreatic Cancer34:49 - Future Directions and Targeted Therapies --- RESOURCES APOLLO Randomized Phase II Studyhttps://clinicaltrials.gov/study/NCT04858334 PRODIGE 29-UCGI 26 (NEOPAN) Phase III Trialhttps://ascopubs.org/doi/10.1200/JCO-24-02210 ALLIANCE A021806 Phase III Trialhttps://doi.org/10.1245/s10434-024-15817-5 NORPACT-1 Phase II Trialhttps://pubmed.ncbi.nlm.nih.gov/38237621/ Dutch Randomized Phase III PREOPANC Trialhttps://pubmed.ncbi.nlm.nih.gov/32105518/ SWOG S1505 Randomized Clinical Trialhttps://pubmed.ncbi.nlm.nih.gov/32740235/ ALLIANCE A021501 Phase II Randomized Clinical Trialhttps://pubmed.ncbi.nlm.nih.gov/35834226/ LAP07 Randomized Clinical Trialhttps://pubmed.ncbi.nlm.nih.gov/27139057/ LAP100 Phase III Trialhttps://clinicaltrials.gov/study/NCT06958328 Meta-analysis on Arterial Resections in Pancreatic Cancerhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12070998/ PANOVA-3 Phase III Studyhttps://ascopubs.org/doi/10.1200/JCO-25-00746 NRG-GI011 Clinical Trial: Openinghttps://www.nrgoncology.org/patients/patient-study-webpages/nrg-gi011-testing-higher-dose-rt-for-locally-advanced-pancreatic-cancer

Metastatic pancreatic cancer is no longer a ‘one size fits all’ diagnosis. In this episode of the BackTable Tumor Board Podcast, medical oncologist Dr. Jon Mizrahi and Dr. Shubham Pant, a professor of GI Medical Oncology at MD Anderson Cancer Center, discuss the evolving landscape of systemic therapy for advanced pancreatic cancer.---SYNPOSISThe doctors cover the current options for first- and second-line chemotherapy treatments, the significance of molecular profiling and germline testing, and the emerging potential of targeting KRAS mutations. The discussion also highlights the importance of supportive and palliative care for patients, focusing on pain management, nutritional support, and the role of pancreatic enzymes. The conversation concludes with speculation on the future of pancreatic cancer treatment and the need for improved access to clinical trials.---TIMESTAMPS00:00 - Introduction02:32 - First-Line Therapy Options10:31 - Second-Line Therapy Options20:18 - Challenges in Pancreatic Cancer Immunotherapy26:47 - Supportive Care and Quality of Life35:57 - Disparities in Pancreatic Cancer Treatment38:58 - Conclusion and Future Directions---RESOURCESAdagrasib Clinical Trialhttps://www.clinicaltrials.gov/study/NCT05853575

Is the open thoracotomy becoming outdated as robotic surgery and advanced ablation techniques take center stage in lung cancer treatment? In the final discussion of the 2025 NSCLC Creator Weekend™ series, our virtual tumor board of interventional radiologists and pulmonologists from leading medical institutions discuss recent surgical and interventional advancements in the treatment of lung cancer. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The conversation covers the contemporary role of PET scans, endobronchial ultrasound (EBUS), mediastinal staging, and the importance of perioperative systemic therapy. The doctors explore surgical and non-surgical methods for treating lung cancer, including lymph node dissection, criteria for resection, and the advantages of minimally invasive approaches such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgeries. A key focus of this episode is the decision-making process for treating multifocal lung cancers while preserving lung function, and the use of combined therapies like ablation and radiation. The episode concludes with a detailed case study illustrating the long-term management of a patient with multiple lung adenocarcinomas over several years, highlighting the multidisciplinary approach required in such complex scenarios. --- TIMESTAMPS 00:00 - Introduction10:07 - Patient Selection and Comorbid Conditions27:29 - Surgical Margins and Resection Strategies42:11 - Understanding Upstaging in Cancer Treatment53:27 - Technical and Clinical Resectability56:13 - Case Study: Managing Multifocal Lung Cancer01:11:41 - Long-Term Outcomes and Treatment Strategies --- RESOURCES CALGB 140503 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2212083 JCOG0802 Trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02333-3/abstract

Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn’t an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Topics include the prioritization of treatment versus tissue acquisition, the nuances of bronchoscopic versus percutaneous biopsies, and the latest advancements in robotic and cryo-biopsy techniques. The experts also share their approaches to managing pneumothorax, the value of multidisciplinary collaboration, and case studies that highlight personalized patient care. Listeners gain valuable insights into the evolving landscape of thoracic oncology procedures and the importance of patient-centered decision-making. --- TIMESTAMPS 00:00 - Introduction04:12 - Cryobiopy vs. Non-Cryobiopsy08:43 - Biopsy and Ablation: Strategies and Considerations15:31 - Post-Therapy Imaging and Follow-Up25:18 - Treatment Options and Patient Decisions27:08 - Evaluating Ablation Techniques28:59 - Managing Lung Cancer Recurrence39:41 - Case Study: Young Male with Ground Glass Nodule43:15 - Concluding Thoughts

Collaboration between interventional radiology and radiation oncology has enabled high-dose brachytherapy in central lung lesions that were previously untreatable. This episode of the 2025 NSCLC Creator Weekend™ series offers a deep dive into recent advancements in lung ablation and brachytherapy techniques for primary lung cancer. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Key discussion points include ablation zone sizes, confirmation methods for effective treatment, and the integration of different modalities such as microwave and cryoablation. Our tumor board panel also explores the practical and logistic challenges of implementing high-dose brachytherapy, especially for central lesions, and its role in palliative care. Despite the intricate processes and potential complications like pneumothorax, these methods show promising local control rates and provide crucial options for non-operative candidates. --- TIMESTAMPS 00:00 - Introduction and Overview of Lung Ablation07:01 - Microwave Ablation and Ground Glass Attenuation17:53 - Artificial Pneumothorax Techniques27:09 - Technical Aspects and Innovations32:35 - Bronchial Brachytherapy Techniques37:47 - Conclusion and Credits --- RESOURCES 2021 Central Lesion Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8186067/

Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, including interventional radiologists, pulmonologists, and a radiation oncologist, discusses the intricacies of photon versus proton therapies, the physics behind radiation treatment, and the evolving landscape of ablation technologies. The conversation covers the efficacy and limitations of different treatments, patient selection criteria, and the role of newer technologies like electroporation and robotic-assisted bronchoscopy in enhancing precision and outcomes. Additionally, the panel addresses the practical challenges of intraprocedural imaging, the importance of adequate margins, and the complexities of managing local recurrences and radiation-induced toxicities. --- TIMESTAMPS 00:00 - Tumor Ablation and Recurrence Rates12:53 - Advancements in Ablation Technologies23:31 - Bronchoscopic Approaches in Lung Cancer Treatment38:46 - Challenges in Radiation Dose and Delivery49:21 - Ablation and Radiation Margins01:07:19 - Final Thoughts --- RESOURCES Thierry de Baere Paper on Ablation Margins https://pmc.ncbi.nlm.nih.gov/articles/PMC9815739/

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient’s treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, featuring specialists from various institutions, discusses the specifics of sequencing therapies, the impact of targeted and immunotherapies, and the nuances of treating different patient profiles, including non-smokers and those with specific genetic mutations. The conversation also touches on the integration of new staging systems, the benefits of multidisciplinary clinics, and the ongoing evolution of cancer treatment trials. The discussion aims to provide clarity on the latest advancements and future directions in managing lung cancer, emphasizing the importance of tailored treatment plans and the potential of emerging technologies. --- TIMESTAMPS 00:00 - Introduction05:16 - Molecular Diagnostics and Liquid Biopsy21:43 - Targeted Therapy Options27:29 - Managing Toxicities and Treatment Strategies33:13 - Challenges with Immunotherapy in Special Cases34:07 - Lung Transplantation in Cancer Patients48:38 - Multidisciplinary Clinics and Collaboration01:06:29 - Future Directions --- RESOURCES ADAURA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Gomez NSCLChttps://pmc.ncbi.nlm.nih.gov/articles/PMC5143183/

When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS Our mock tumor board consists of surgeons, medical oncologists, and radiation oncologists to deliberate and determine the best treatment plan. The specialists explore diagnostic and treatment options, including neoadjuvant chemoimmunotherapy, invasive mediastinal staging, and the potential for surgical resection or radiation therapy. --- TIMESTAMPS 00:00 - Introduction05:01 - Approach to Isolated Brain Metastasis09:09 - Radiation Therapy Considerations12:06 - Imaging and Follow-Up Strategies14:39 - Resectability and Surgical Decisions19:10 - Conclusion --- RESOURCES PACIFIC Clinical Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

When treating head and neck cancer, how can you tell the difference between true disease progression and pseudoprogression? In this episode of the BackTable Podcast, we discuss the practical implementation of the KEYNOTE-689 trial published in the New England Journal of Medicine, which demonstrated the benefit of adding neoadjuvant and adjuvant immunotherapy to standard head and neck cancer care. Our tumor board panel includes Dr. Mihir Patel, a head and neck surgeon from UNC Chapel Hill, Dr. Siddharth Sheth, a head and neck medical oncologist from UNC, Dr. Jennifer Johnson, a professor of medical oncology and otolaryngology at Sidney Kimmel Comprehensive Cancer Center, and Dr. Adam Luginbuhl, a head and neck surgical oncologist at Thomas Jefferson University.---SYNPOSISThe doctors address the trial's practical implications, patient selection, case management, dealing with tumor progression, and the integration of multidisciplinary care. They also emphasize the importance of communication, real-world application of trial protocols, and the potential benefits and challenges of such therapies.---TIMESTAMPS00:00 - Introduction03:18 - Discussing the New Indication for Immunotherapy11:42 - Challenges and Practical Implementation22:48 - Managing Tumor Progression: A Case Study28:07 - Exploring Treatment Options: Surgery vs. Chemotherapy36:46 - Operational Challenges and Future Directions43:58 - Concluding Thoughts and Future Directions---RESOURCESKeynote 689https://www.nejm.org/doi/full/10.1056/NEJMoa2415434

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.---SYNPOSISThe doctors discuss the trial details, FDA approval, and practical challenges of integrating this new paradigm into clinical practice. The conversation covers critical points such as the necessity of CPS score testing, timely drug administration, patient monitoring, and the importance of collaboration among multidisciplinary teams.---TIMESTAMPS00:00 - Introduction02:18 - Keynote-689 Trial Explained04:42 - Implementation Challenges and Strategies06:40 - Practical Considerations for CPS Testing13:59 - Case Studies and Real-World Applications30:48 - Future Directions and Final Thoughts---RESOURCESKeynote-689https://www.nejm.org/doi/full/10.1056/NEJMoa24154342004 Cisplatin Phase III Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa032646

One of the most common dilemmas in urologic oncology: what do you do when a patient has T1 disease in both the bladder and the ureter? In the final episode of the 2025 NMIBC Creator Weekend™ series, Dr. Vignesh Packiam, Dr. Mark Tyson and Dr. Sarah Psutka share how they approach complex bladder cancer cases with upper tract involvement. --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The doctors discuss complex bladder cancer cases, sequencing treatments for patients with dual ureteral and bladder T1 disease, the impact of cystectomy on quality of life, and the use of blue light cystoscopy and intravesical therapy. They also delve into the rise of bladder cancer in younger patients, considerations for low-grade intermediate-risk disease, and emerging therapeutic options. --- TIMESTAMPS 00:00 - Introduction05:52 - Upper Tract Positive Cytology Dilemma09:10 - Cystectomy Considerations15:55 - Developing Better Patient-Reported Outcomes20:26 - Challenges with New Therapeutics26:31 - Deescalating Treatment for Low-Grade Cancer33:29 - Closing Remarks

When standard therapy fails, it does not have to be the end of the road for high-risk bladder cancer patients. Modern treatments, biomarkers, and clinical studies have opened up new avenues for treating recurrent non-muscle invasive bladder cancer (NMIBC). The penultimate episode of the 2025 NMIBC Creator Weekend™ series features urologic oncologists Dr. Vignesh Packiam, Dr. Mark Tyson, and Dr. Sarah Psutka discussing how they navigate complex bladder cancer scenarios. --- This podcast is supported by: Ferring Pharmaceuticals --- SYNPOSIS The doctors share treatment strategies, staging processes, and post-therapy patient management techniques. They address recurrent disease, approaches to different stages of cancer, the role of biomarkers in determining treatment paths, and considerations for both high-risk and intermediate-risk patients. Additionally, the episode touches on new treatments, clinical trials, and patient quality of life post-treatment. --- TIMESTAMPS 00:00 - Introduction02:08 - Case Study: Initial Patient Assessment04:59 - Surgical Considerations and Techniques10:22 - Managing Bladder Cancer Recurrence11:15 - Treatment Options and Clinical Trials15:12 - Advanced Treatment Strategies28:14 - Closing Remarks and Credits

With the right protocols (and the right team!), urology clinics can proactively manage the side effects of intravesical therapy. This in-studio episode from the 2025 NMIBC Creator Weekend™ series features unique perspectives from Vanderbilt nurse practitioner Meredith Donahue and surgical neuro-oncology nurse Brynn Moore, both with focuses in urologic oncology. Hosted by Dr. Ruchika Talwar, we cover the practical and logistical considerations in intravesical therapy administration. --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS Donahue and Moore share their experiences with intravesical therapy, discussing practical issues such as patient management, scheduling, and handling side effects. They emphasize the importance of creating a supportive environment in clinics, proactive treatment plans, and ensuring effective communication among the multidisciplinary team. They also share resources and tips for nurses and nurse practitioners new to urologic oncology. --- TIMESTAMPS 00:00 - Introduction07:09 - Multidisciplinary Team Dynamics11:34 - Resources for Patients18:55 - Transvaginal Estrogen Cream26:56 - Optimizing Intravesical Therapy Clinics35:57 - The Importance of Multidisciplinary Collaboration36:27 - Conclusion

As new genetic and AI-powered tools emerge for bladder cancer screening, are we getting closer to reducing the need for invasive cystoscopies? In part five of the 2025 BackTable NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam engages in an insightful discussion with Dr. Sarah Psutka from the University of Washington and Dr. Katie Murray from NYU about the complexities and potential benefits of using biomarkers in non-muscle invasive bladder cancer (NMIBC). --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The conversation covers the current challenges of interpreting positive biomarkers without clinical correlates, the gold standard of biopsies, and the potential of various biomarkers such as urine cytology, FISH, and newer genomic tests like the Decipher Bladder Genomic Classifier. They also touch upon the role of AI in pathology, the cost implications of biomarkers, and how these tools might influence future clinical practices and patient decisions. The episode emphasizes the need for precision medicine, careful patient counseling, and the impact of false positives and negatives on both patients and healthcare providers. --- TIMESTAMPS 00:00 - Introduction05:25 - Challenges with Current Biomarkers08:10 - New Biomarkers and Genomic Classifiers21:10 - AI and Pathology in Bladder Cancer35:13 - Screening and Future Directions41:20 - Challenges and Future Directions in Bladder Cancer Surveillance57:51 - Conclusion

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer. --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes. --- TIMESTAMPS 00:00 - Introduction02:04 - The Role of Medical Oncologists in Bladder Cancer12:58 - Combination Therapies and Patient Outcomes21:18 - The CREST Study26:59 - Managing Adverse Events34:44 - Collaboration Between Urologists and Oncologists41:06 - Conclusion and Final Thoughts

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology. --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology. --- TIMESTAMPS 00:00 - Introduction05:09 - Challenges and Strategies in Treatment10:55 - Bladder Sparing Therapies21:41 - Practical Tips for Therapy Administration30:39 - Challenges and Considerations in Reinduction37:05 - Clinical Trials and Future Directions44:11 - Counseling Patients on Treatment Options57:36 - Concluding Thoughts and Future Outlook

When a patient is diagnosed with non-muscle invasive bladder cancer (NMIBC), how do you tailor the conversation and treatment plan to their individual needs (and fears)? In part two of the 2025 NMIBC Creator Weekend™ series, host Dr. Vignesh Packiam is joined by Dr. Sima Porten from UCSF and Dr. Patrick Hensley from the University of Kentucky to discuss patient-centered diagnostic and therapeutic approaches for non-muscle invasive bladder cancer. --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The conversation covers initial patient consultations, discussing diagnoses, personalized treatment options such as BCG, gemcitabine, clinical trials, and managing side effects. The experts emphasize the importance of clear communication, understanding patient preferences, and tailoring approaches to enhance the patient's quality of life. They also explore insights from recent studies like the CISTO trial and highlight novel research directions. --- TIMESTAMPS 00:00 - Introduction04:28 - Counseling Patients on Diagnostic Findings12:03 - Symptom Management and Patient Care19:30 - Post-Procedure Care and Counseling28:50 - Recovery After TURBT: Medications and Patient Care44:16 - The Impact of Radical Cystectomy on Quality of Life49:15 - Final Thoughts and Future Directions in Bladder Cancer Care

How are leading urologic oncologists using advanced biomarkers and artificial intelligence to refine the diagnosis and management of non-muscle invasive bladder cancer (NMIBC)? In the opening episode of our 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt engages in an insightful, in-studio discussion with Dr. Anne Schuckman and Dr. Piyush Agarwal about contemporary strategies and challenges in the diagnosis of non-muscle invasive bladder cancer. --- This podcast is supported by: ⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The doctors emphasize the importance of having an experienced cytopathologist and discuss the use of different biomarkers and imaging modalities in bladder cancer diagnosis. The conversation delves into risk stratification, patient management strategies, and the evolving role of technology and artificial intelligence in enhancing diagnostic accuracy. The experts also share their perspectives on future advancements and their potential impact on clinical practice. --- TIMESTAMPS 00:00 - Introduction04:05 - Surveillance and Follow-Up Strategies10:10 - Biomarkers in Bladder Cancer18:02 - Blue Light Cystoscopy and Patient Comfort30:56 - Risk Assessment and Counseling42:56 - Future of Bladder Cancer Diagnostics47:00 - Concluding Thoughts

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases. --- This podcast is supported by:Ferring Pharmaceuticals --- SYNPOSIS The conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care. --- TIMESTAMPS 0:00 - Introduction02:20 - Case 1 (Incidental Renal Mass)16:52 - Case 2 (Bilateral Renal Masses)37:22 - Case 3 (Locally Advanced Renal Mass)56:34 - Case 4 (Symptomatic, Metastatic Disease)01:14:00 - Final Takeaways

When it comes to spinal oncology, no single specialty holds all the answers. In this episode of the BackTable Podcast, host Dr. Alexa Levey, an interventional radiologist from Yale School of Medicine, is joined by Dr. Mark Amsbaugh, a radiation oncologist, and Dr. Ran Lador, an orthopedic spine surgeon, both from the University of Texas McGovern Medical School. The discussion explores complexities and innovations in the multidisciplinary treatment of spinal tumors. --- This podcast is supported by:Ferring Pharmaceuticals--- SYNPOSIS Dr. Amsbaugh and Dr. Lador highlight their cohesive, patient-centered approach at Memorial Hermann, integrating various specialties including surgery, radiation oncology, and interventional radiology. The episode emphasizes the importance of collaborative techniques, advances in minimally invasive surgeries, the role of stereotactic radiosurgery, and the critical nature of personalized patient care in improving outcomes for patients with spinal tumors. --- TIMESTAMPS 00:00 - Introduction01:20 - Multidisciplinary Approach to Spinal Tumors at Memorial Hermann10:22 - Surgical Techniques and Timing for Radiation Treatments 12:25 - Approach to Collaborative Treatment Planning25:45 - Connection Between Surgical and Radiation Oncology in Patient Care31:08 - The Role of Vertebral Augmentation in Spinal Oncology40:08 - Multimodal Pain Management Strategies47:35 - Thoughts on Future Directions in Spinal Oncology and Conclusion --- RESOURCES Dr. Mark Amsbaugh, MDhttps://med.uth.edu/neurosciences/dr-mark-j-amsbaugh-md/ Dr. Ran Lador, MDhttps://med.uth.edu/ortho/2022/11/02/ran-lador-md/ Dr. Alexa Levey, MDhttps://medicine.yale.edu/profile/alexa-levey/

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer. --- This podcast is supported by:Ferring Pharmaceuticals --- SYNPOSIS The multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes. --- TIMESTAMPS 0:00 - Introduction1:48 - Active Surveillance in Low-Risk Prostate Cancer7:08 - Molecular Testing and Risk Stratification8:28 - Radiation Therapy Approaches20:16 - PSA Recurrence and PSMA PET Scans32:40 - The Role of ADT37:15 - PSMA PET Scans40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer46:54 - Treatment Intensification vs. De-Intensification Trials55:59 - Castration-Resistant Prostate Cancer

How do you effectively treat your bladder cancer population with an insufficient supply of BCG? Dr. Amy Luckenbaugh, a urologic oncologist at Vanderbilt University Medical Center, joins host Dr. Ruchika Talwar to highlight challenges and solutions to managing bladder cancer amidst ongoing BCG shortages. --- This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025. --- SYNPOSIS Dr. Luckenbaugh and Dr. Talwar delve into the history and significance of BCG in bladder cancer treatment, exploring the reasons behind the shortages and discussing various coping strategies, including split dosing and alternative intravesical therapies like gemcitabine, docetaxel, and the new mitomycin hydrogel. The conversation also covers emerging treatments for high-risk patients, the role of radical cystectomy, and the importance of standardization and innovation in dealing with medication shortages. Dr. Luckenbaugh highlights the importance of patient quality of life, cost considerations, and the need for resilient pharmaceutical supply chains. --- TIMESTAMPS 00:00 - Introduction01:56 - History and Importance of BCG in Bladder Cancer03:21 - Challenges and Shortages of BCG06:36 - Managing BCG Shortages in Clinical Practice12:33 - New Alternatives and Treatments for Bladder Cancer23:28 - The Role of Cystectomy in Bladder Cancer Treatment26:12 - Future Directions and Final Thoughts --- RESOURCES BCG Shortage AUA Recommendations:https://www.auanet.org/about-us/bcg-shortage-info Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre:https://pmc.ncbi.nlm.nih.gov/articles/PMC11951178/ Bladder Cancer Advocacy Network (BCAN):https://bcan.org/ Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)https://pubmed.ncbi.nlm.nih.gov/39446087/b FDA Approves Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mitomycin-intravesical-solution-recurrent-low-grade-intermediate-risk-non-muscle TAR-200 - SunRISe-3 Study:https://www.jnjmedicalconnect.com/products/tar-200/medical-content/tar-200-sunrise-3-study First results from TAR-200 - SunRISe-1 Study:https://www.jnj.com/media-center/press-releases/johnson-johnsons-tar-200-monotherapy-achieves-high-disease-free-survival-of-more-than-80-percent-in-bcg-unresponsive-high-risk-papillary-nmibc N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review:https://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/

With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer. --- This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025. --- SYNPOSIS The doctors break down the nuances of defining this risk category and the clinical gray zones that complicate treatment decisions. Dr. Herrell shares her patient-centered approach to surveillance and therapy, and introduces promising new agents, including Anktiva, UGN-102, and the gemcitabine-releasing TAR-200 "pretzel" device. The discussion also highlights how advances in molecular profiling are reshaping care strategies.This episode underscores the urgent need for clearer guidelines and continued innovation to improve outcomes and quality of life for patients with this nuanced disease subtype. --- TIMESTAMPS 00:00 - Introduction02:03 - Defining Intermediate Risk Bladder Cancer06:12 - Intravesical Therapy Options08:47 - Quality of Life and Patient Counseling10:18 - New Treatments on the Horizon12:56 - Practical Tips for TURBT Recovery17:03 - In-Office Procedure Management21:38 - Managing Symptoms and Quality of Life31:50 - A Note on Smoking Cessation33:37 - Conclusion and Future Directions

Counseling patients with intermediate-risk non-muscle invasive bladder cancer can be complex, with a wide range of treatment options and care pathways. In this episode of BackTable, urologic oncologists Dr. Ruchika Talwar and Dr. Kelly Bree explore how to approach this challenge with clarity and compassion. --- This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025. --- SYNPOSIS They emphasize a shift toward patient-centered, less aggressive treatment strategies, highlighting the importance of quality of life in clinical decision-making. The discussion includes risk stratification, the use of intravesical gemcitabine, and ongoing clinical trials. Dr. Bree also offers actionable tips for optimizing patient preparation and recovery. This episode underscores the growing importance of listening to patient voices to shape future standards of care. --- TIMESTAMPS 00:00 - Introduction02:09 - Risk Stratification and Treatment Approaches06:12 - Intravesical Therapy Options08:47 - Quality of Life and Patient Counseling12:56 - Practical Tips for TURBT Recovery17:03 - In-Office Procedure Management21:23 - Resources and Support for Patients24:13 - Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

How do the experts balance organ preservation, oncologic control, and emerging therapies in both localized and metastatic cases of penile cancer? This episode of BackTable Tumor Board focuses on penile cancer diagnosis and treatment, featuring urologic oncologist Dr. Charles Peyton (UAB), radiation oncologist Dr. Juanita Crook (UBC), and medical oncologist Dr. Andrea Apolo (NCI). --- This podcast is supported by:Ferring Pharmaceuticals --- SYNPOSIS This session covers case studies ranging from localized to advanced penile cancer, diagnostic practices, imaging preferences (MRI vs. CT), and treatment options, including surgery, brachytherapy, chemoradiation, and neoadjuvant chemotherapy. The multidisciplinary team highlights the complexities of treating this rare cancer, underscores the importance of physical exams, and stresses the necessity of personalized treatment plans. They also delve into the challenges of managing metastatic stages, potential salvage therapies, and the importance of clinical trials in enhancing treatment efficacy. The doctors also emphasize the potential of immunotherapy and chemotherapy combinations for metastatic disease. --- TIMESTAMPS 00:00 - Introduction02:23 - Imaging Preferences03:29 - Biopsy vs Immediate Surgery06:04 - Lymph Node Dissection vs Radiation13:48 - Brachytherapy Techniques and Case Study23:21 - Challenges in Advanced Penile Cancer27:03 - Chemotherapy and Chemoradiation30:15 - InPACT Trial37:12 - Salvage Therapies and Exploring New Treatment Frontiers44:25 - Support and Awareness for Penile Cancer51:29 - Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

With so many treatment modalities for upper tract urothelial carcinoma, how does new evidence inform optimal care? In this episode of BackTable Tumor Board, urologic oncologist Dr. Nirmish Singla (Johns Hopkins), medical oncologist Dr. Jeannie Hoffman-Censits (Johns Hopkins), and urologic oncologist Dr. Bogdana Schmidt discuss treatment and diagnosis of upper tract urothelial carcinoma (UTUC). --- This podcast is supported by: ⁠⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The discussion covers real-world UTUC cases, highlighting diagnostic challenges, treatment options, and evidence-based management strategies. They address scenarios ranging from localized to advanced UTUC, the role of systemic therapies, perioperative treatments, and the potential for novel approaches with immune checkpoint inhibitors. The episode underscores the evolving landscape of UTUC treatment and the importance of clinical trials and emerging biomarkers in improving patient outcomes. --- TIMESTAMPS 00:00 - Introduction 02:49 - Case Study 1: 66-Year-Old Male with UTUC11:19 - Case Study 2: 73-Year-Old Male with High-Grade Urothelial Carcinoma28:11 - Intravesical Chemotherapy Protocols30:44 - Case Study 3: 57-Year-Old Male with Recurrent Urothelial Cancer41:25 Clinical Trials and Emerging Treatments45:40 Case Study: 55-Year-Old Female with Bulky Lymphadenopathy 56:45 Concluding Remarks and Future Directions --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

What if the key to better cancer outcomes lies not just in surgery or chemotherapy, but also in mindfulness, movement, and diet? In this episode of the BackTable Tumor Board, host Dr. Aditya Bagrodia interviews urologic oncologist Dr. Viraj Master, Professor of Urology at Emory University, about his role in developing the integrative oncology and survivorship service line at Winship Cancer Institute. --- This podcast is supported by: ⁠⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS They discuss the evidence-based use of complementary therapies alongside conventional cancer treatments, touching on various integrative methods including diet, exercise, mindfulness, acupuncture, yoga, and supplements. Dr. Master emphasizes the importance of physicians being open to these practices and understanding their potential benefits for improving patient outcomes and quality of life, even in highly acute cases like muscle-invasive bladder cancer. The conversation covers the importance of honesty and understanding across patient journeys–from initial diagnosis to survivorship–highlighting the value of holistic approaches in cancer care. --- TIMESTAMPS 00:00 - Integrative Oncology: Definitions and Basics06:28 - Exercise and Its Impact on Cancer Treatment08:12 - Physician Perspectives on Complementary Medicine20:58 - Acupuncture and Acupressure in Cancer Care25:28 - Practical Implementation of Integrative Approaches31:30 - Supplements and Immuno Nutrition36:25 - Cannabis, CBD, and Ayurveda in Cancer Care44:39 - Conclusion and Final Thoughts --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

How can pediatric and adult urologists team up to tackle complex cancer cases? In this episode of the BackTable Tumor Board, host Dr. Amanda Buchanan, Division Chief of Pediatric Urology at the University of Kentucky, is joined by her colleagues Dr. Patrick Hensley, an adult urologic oncologist, and Dave Rodeberg, Division Chief of Pediatric Surgery. Their discussion centers around the importance of professional collaboration in urologic oncology care in order to improve patient outcomes. --- This podcast is supported by: ⁠⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS The urologists discuss topics such as the experiences and benefits of interdisciplinary collaboration in complex cases and the role of pediatric urologists in treating adolescent and young adult patients. They also provide insights into the Children's Oncology Group (COG) studies and their intersections with adult oncology research. The episode concludes with practical advice for other institutions aiming to improve collaborative efforts between pediatric and adult urology departments. --- TIMESTAMPS 00:00 - Importance of Collaboration in Urologic Oncology05:38 - Challenges in Multidisciplinary Collaboration08:30 - Pediatric Urologists’ Role in Testicular Cancer11:05 - Clinical Trials and Research Collaborations14:21 - Navigating COG and Adult Oncology Groups19:03 - Collaborative Approach to Kidney Tumors29:31 - Resident Education and Collaboration35:22 - Final Thoughts --- RESOURCES Society of Urologic Oncology:https://suonet.org/home.aspx Children’s Oncology Grouphttps://www.childrensoncologygroup.org/

How can urologists and radiologists work together to improve kidney cancer treatment? In this episode, BackTable Tumor Board brings together Dr. Jason Abel (Professor of Urology and Radiology at the University of Wisconsin), Dr. Louis Hinshaw (Section Chief of Abdominal Imaging Intervention at the University of Wisconsin), and Dr. Ruchika Talwar (Assistant Professor of Urologic Oncology at Vanderbilt) for a multidisciplinary conversation regarding the treatment of renal tumors. --- This podcast is supported by: ⁠⁠Ferring Pharmaceuticals⁠ --- SYNPOSIS Their discussion covers the history and benefits of collaboration between urology and interventional radiology (IR), advances in image-guided procedural technologies, and the importance of teamwork in improving patient outcomes. The episode also considers the encouraging, but limited data in IR treatments such as microwave ablation and discusses the lasting role for surgery. Finally, Dr. Abel and Dr. Hinshaw share their experiences in establishing a successful interdisciplinary kidney cancer program. Ultimately, they conclude that the future of renal tumor treatment lies not in silos, but in collaboration. --- TIMESTAMPS 00:00 - Multidisciplinary Collaboration in Renal Tumor Treatment05:59 - Advancements in Ablation Techniques: From Cryoablation to Microwave10:13 - Ablation vs. Surgery: Patient Selection and Clinical Decision Making14:00 - Technical Considerations and Complications in Ablation Procedures24:19 - Patient Experience and Recovery Post-Ablation36:17 - Importance of Teamwork in Modern Medicine --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

What does it take to deliver truly personalized, multidisciplinary care in testicular cancer? Get an inside look in this episode of BackTable Tumor Board, where renowned testicular cancer experts Dr. Nabil Adra and Dr. Richard Matulewicz join host Dr. Aditya Bagrodia for a virtual tumor board session on the nuanced management of germ cell tumors. --- This podcast is supported by: ⁠Ferring Pharmaceuticals --- SYNPOSIS The expert panel uses specific patient cases to review their decision-making processes on the use of surgery, chemotherapy, and radiation. They highlight the importance of a multidisciplinary approach, particularly for advanced disease and challenging surgical scenarios. The episode reviews patient-specific factors, standard treatment protocols, post-treatment surveillance, and the latest research. This episode also highlights the benefits of personalized cancer care. --- TIMESTAMPS 00:00 - Case Presentation: 23-Year-Old Male with Testicular Mass09:53 - Surveillance vs. Adjuvant Therapy Debate13:53 - Recurrence, Comprehensive Staging, and Next Steps23:09 - Case Study: 44-Year-Old with Mixed Non-Seminoma Germ Cell Tumor27:47 - Surveillance and Surgery Recommendations28:11 - Case Study: 17-Year-Old with Developmental Delay and Cancer30:10 - Chemotherapy, Surgical Timing, and Prognosis44:58 - Case Study: 21-Year-Old with Scrotal Swelling47:12 - Surgical Considerations and Multidisciplinary Approach --- RESOURCES Society of Urologic Oncologyhttps://suonet.org/home.aspx

There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.---This podcast is supported by an educational grant from Guerbet.---SYNPOSISThe doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.---TIMESTAMPS00:00 - Introduction 03:35 - HCC from an Oncologic Perspective 05:33 - Radiological Perspective on Liver Cancer06:50 - Referral Patterns and Organizing a Multidisciplinary Approach18:01 - Explaining TACE and Variations in the Procedure27:27 - Choosing the Right Procedure for HCC36:13 - Making a Decision on Medical Treatment Candidacy 42:23 - Importance of Data Driven HCC Treatment, Practical Insights, and Studies to Know55:30 - Planning an Approach for a TACE Procedure01:02:26 - Final Thoughts and Future Prospects in Liver Cancer Treatment---RESOURCESBarcelona Staging System:https://www.ncbi.nlm.nih.gov/books/NBK569796/table/Ch3-t0001/TRACE Trial:https://pubs.rsna.org/doi/full/10.1148/radiol.211806PREMIERE Trial:https://www.gastrojournal.org/article/S0016-5085(16)34971-X/fulltextEMERALD-1 Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA432LEAP O12 Study:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Medical, surgical, radiation, and interventional oncology all play vital roles in delivering care to patients battling liver cancer. How do we optimize outcomes when so many specialties have something to offer the same patient? The answer is collaborative oncology. Dr. Robert Martin (Director of Surgical Oncology, University of Louisville) and pioneer in liver-directed therapies, joins host Dr. Sabeen Dhand to discuss a collaborative approach to oncology and recent advances in locoregional therapy. --- This podcast is supported by: RADPAD® Radiation Protection https://www.radpad.com/ --- SYNPOSIS Dr. Martin discusses the importance of a growth mindset in advancing medical techniques and fostering collaborations between specialists. He then shares insights into minimally invasive procedures, such as microwave ablation and irreversible electroporation (IRE). The doctors also touch on the evolution of liver cancer treatments, emphasizing the significance of clinical trials on the horizon. To conclude, Dr. Martin encourages young professionals in surgery and interventional radiology to stay open-minded, be life-long learners, and find synergistic ways to integrate new technologies into patient care. --- TIMESTAMPS 00:00 - Introduction 02:31 - Dr. Martin’s Background and Career Path 06:18 - Evolution of Liver Directed Therapies 10:12 - Collaboration Between Specialties 18:34 - Clinical Trials and Emerging Therapies 36:08 - Advice for Young Professionals 39:15 - Conclusion --- RESOURCES Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of HCC: https://clinicaltrials.gov/study/NCT05953337?term=NCT05953337&rank=1 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1): https://clinicaltrials.gov/study/NCT05688280 Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3: https://immunophotonics.com/news/immunophotonics-cirse-and-next-research-announce-innovative-phase-2-3-clinical-trial-injectabl-3/

Do you ever wish you could be a fly on the wall at a tumor board meeting? In this episode of BackTable, we’re excited to give you an insider’s view of the real case discussions that take place during hepatocellular carcinoma (HCC) tumor boards. Host Dr. Zach Berman sits down with a multidisciplinary team, including Drs. Adam Burgoyne (medical oncologist), Heather Patton (hepatologist), Siddharth Padia (interventional radiologist), and Gabriel Schnickel (transplant and hepatobiliary surgeon). Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125743 --- This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific. --- SYNPOSIS The team walks through a range of diverse HCC cases, reviewing patient histories, imaging, and treatment options. They cover eight cases in total, each featuring patients with varying treatment histories, comorbidities, liver function, and lesion characteristics. For the full educational experience, we recommend watching the video format on our YouTube channel. --- TIMESTAMPS 00:00 - Introduction 00:47 - Case 1: Small Lesion in a Young Patient 05:01 - Case 2: Moderate Sized Lesion in an Older Patient 11:10 - Case 3: Multifocal HCC with Dominant Lesion 21:09 - Case 4: Dominant Lesion with Portal Hypertension 32:08 - Case 5: Ruptured Solitary Lesion 34:34 - Case 6: Rupture with Multifocal Lesions 44:08 - Case 7: Portal Vein Invasion 52:12 - Case 8: Metastatic HCC After Transplant --- RESOURCES CME Accreditation Information: https://f7cae4ec-b69e-490d-9e0f-19b16a6f146d.usrfiles.com/ugd/f7cae4_a7c37ea3cd1b4d3fa53d5edf8dfe255b.pdf